Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Strata Critical Medical (SRTA) Share-based Compensation (2020 - 2025)

Strata Critical Medical (SRTA) has disclosed Share-based Compensation for 6 consecutive years, with $6.6 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation rose 45.51% to $6.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $17.8 million through Dec 2025, down 10.36% year-over-year, with the annual reading at $17.8 million for FY2025, 10.36% down from the prior year.
  • Share-based Compensation for Q4 2025 was $6.6 million at Strata Critical Medical, up from $1.7 million in the prior quarter.
  • The five-year high for Share-based Compensation was $8.3 million in Q3 2021, with the low at $656000.0 in Q2 2021.
  • Average Share-based Compensation over 5 years is $3.8 million, with a median of $3.3 million recorded in 2023.
  • The sharpest move saw Share-based Compensation skyrocketed 9271.43% in 2021, then crashed 68.9% in 2025.
  • Over 5 years, Share-based Compensation stood at $2.9 million in 2021, then decreased by 9.59% to $2.6 million in 2022, then increased by 18.98% to $3.2 million in 2023, then skyrocketed by 43.55% to $4.5 million in 2024, then surged by 45.51% to $6.6 million in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $6.6 million, $1.7 million, and $5.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.